IL17A and acute respiratory distress syndrome: The GSK3B inhibitor reduces the production of IL-6, TNFα, IL-17, and IL-1β in the BALF of mice with lipopolysaccharide-induced acute respiratory distress syndrome, thus relieving the lung injury [41].